Cytosorbents price to book ratio CTSO

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 10.3×; Jul 2026
10-year median: 5.1×
10-year range: 1.2× to 110×
Peer median: 1.3×

Cytosorbents' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Jul 2026, at 10.3×.

On the days it had one over the last ten years, its median was 5.1×, from 1.2× in Sep 2022 to 110× in Jan 2017.

Price to book ratio over time

median 5.1×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.3×	4.1×	14.2×
2025	4.7×	3.6×	6.3×
2024	4.0×	1.9×	5.0×
2023	2.7×	2.2×	5.9×
2022	1.7×	1.2×	2.4×
2021	2.6×	2.6×	6.1×
2020	4.3×	4.3×	97.9×
2019	18.4×	11.4×	22.2×
2018	12.3×	11.1×	25.7×
2017	19.7×	16.3×	110×
2016	101×	9.6×	102×
2015	15.1×	13.1×	51.0×
2014	n/m a value too high to mean anything
2013	21.3×	17.8×	24.9×
2012	23.1×	19.5×	86.1×
2011	25.3×	12.2×	26.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Cytosorbents' size, closest first, today.

Company	Price to book ratio
CTSOCytosorbents	n/m
NEPHNephros	3.2×
APTAlpha Pro Tech	0.9×
KEQUKewaunee Scientific	1.3×
Peer median	1.3×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Cytosorbents

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.